Sera Prognostics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
March 22, 2023 at 08:12 pm
Share
Sera Prognostics, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported sales was USD 0.065 million compared to USD 0.026 million a year ago. Net loss was USD 9.75 million compared to USD 12.48 million a year ago. Basic loss per share from continuing operations was USD 0.31 compared to USD 0.41 a year ago. Diluted loss per share from continuing operations was USD 0.31 compared to USD 0.41 a year ago.
For the full year, the company reported sales was USD 0.268 million compared to USD 0.082 million a year ago. Net loss was USD 44.19 million compared to USD 35.01 million a year ago. Basic loss per share from continuing operations was USD 1.43 compared to USD 2.33 a year ago. Diluted loss per share from continuing operations was USD 1.43 compared to USD 2.33 a year ago.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant motherâs risk of delivering spontaneously before 37 weeksâ gestation.
SERA PROGNOSTICS, INC. 
